{"pmid":32224294,"title":"[Recommendations CCAFU on the management of cancers of the urogenital system during an epidemic with Coronavirus COVID-19.]","text":["[Recommendations CCAFU on the management of cancers of the urogenital system during an epidemic with Coronavirus COVID-19.]","AIM: The French population is facing the COVID-19 pandemic and the health systems have been reoriented in emergency for the care of patients with coronavirus. The management of cancers of the urinary and male genital tracts must be adapted to this context. MATERIAL AND METHOD: An expert opinion documented by a literature review was formulated by the Cancerology Committee of the French Association of Urology (CCAFU). RESULTS: The medical and surgical management of patients with any cancers of the urinary and male genital tracts must be adapted by modifying the consultation methods, by prioritizing interventions according to the intrinsic prognosis of cancers, taking into account the patient's comorbidities. The protection of urologists from COVID-19 must be considered. CONCLUSION: The CCAFU issues an expert opinion on the measure to be taken to adapt the management of cancers of the male urinary and genital tract to the context of pandemic by COVID-19. [[[fr]]]Resume Objectif: La population francaise est confrontee a la pandemie de COVID-19 et le systemes de sante a ete reoriente en urgence pour la prise en charge des patients atteint du coronavirus. La prise en charge des cancers de l'appareil urinaire et genital masculin doit etre adaptee a ce contexte. Materiel et methode: Un avis d'experts documente par une revue de la litterature a ete formule par le Comite de Cancerologie de l'Association Francaise d'Urologie (CCAFU). Resultats: La prise en charge medicale et chirurgicale des patients atteint de cancers de l'appareil urinaire et genital masculin doit etre adaptee en modifiant les modalites de consultation, en priorisant les interventions en fonction du pronostic intrinseque des cancers en tenant compte des comorbidites du patient. La protection des urologues vis-a-vis du COVID-19 doit etre prise en consideration. CONCLUSION: Le CCAFU emet un avis d'experts quant aux mesures a prendre pour adapter la prise en charge des cancers de l'appareil urinaire et genital masculin au contexte de pandemie par COVID-19.","Prog Urol","Mejean, Arnaud","Roupret, Morgan","Rozet, Francois","Bensalah, Karim","Murez, Thibaut","Game, Xavier","Rebillard, Xavier","Mallet, Richard","Faix, Antoine","Mongiat-Artus, Pierre","Fournier, Georges","Neuzillet, Yann","32224294"],"abstract":["AIM: The French population is facing the COVID-19 pandemic and the health systems have been reoriented in emergency for the care of patients with coronavirus. The management of cancers of the urinary and male genital tracts must be adapted to this context. MATERIAL AND METHOD: An expert opinion documented by a literature review was formulated by the Cancerology Committee of the French Association of Urology (CCAFU). RESULTS: The medical and surgical management of patients with any cancers of the urinary and male genital tracts must be adapted by modifying the consultation methods, by prioritizing interventions according to the intrinsic prognosis of cancers, taking into account the patient's comorbidities. The protection of urologists from COVID-19 must be considered. CONCLUSION: The CCAFU issues an expert opinion on the measure to be taken to adapt the management of cancers of the male urinary and genital tract to the context of pandemic by COVID-19. [[[fr]]]Resume Objectif: La population francaise est confrontee a la pandemie de COVID-19 et le systemes de sante a ete reoriente en urgence pour la prise en charge des patients atteint du coronavirus. La prise en charge des cancers de l'appareil urinaire et genital masculin doit etre adaptee a ce contexte. Materiel et methode: Un avis d'experts documente par une revue de la litterature a ete formule par le Comite de Cancerologie de l'Association Francaise d'Urologie (CCAFU). Resultats: La prise en charge medicale et chirurgicale des patients atteint de cancers de l'appareil urinaire et genital masculin doit etre adaptee en modifiant les modalites de consultation, en priorisant les interventions en fonction du pronostic intrinseque des cancers en tenant compte des comorbidites du patient. La protection des urologues vis-a-vis du COVID-19 doit etre prise en consideration. CONCLUSION: Le CCAFU emet un avis d'experts quant aux mesures a prendre pour adapter la prise en charge des cancers de l'appareil urinaire et genital masculin au contexte de pandemie par COVID-19."],"journal":"Prog Urol","authors":["Mejean, Arnaud","Roupret, Morgan","Rozet, Francois","Bensalah, Karim","Murez, Thibaut","Game, Xavier","Rebillard, Xavier","Mallet, Richard","Faix, Antoine","Mongiat-Artus, Pierre","Fournier, Georges","Neuzillet, Yann"],"date":"2020-04-01T11:00:00Z","year":2020,"_id":"32224294","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.purol.2020.03.009","keywords":["COVID-19","bladder cancer","kidney cancer","penile cancer","prostate cancer","testicular cancer"],"source":"PubMed","locations":["French"],"countries":["France"],"countries_codes":["FRA|France"],"weight":0,"_version_":1662819280321773568,"score":7.334329,"similar":[{"pmid":32125132,"title":"[Expert recommendations on the management of patients with advanced non-small cell lung cancer during epidemic of COVID-19 (Trial version)].","text":["[Expert recommendations on the management of patients with advanced non-small cell lung cancer during epidemic of COVID-19 (Trial version)].","The outbreak of coronavirus disease 2019 (COVID-19) has become a public health emergency of major international concern. Given the systemic immunosuppressive state caused by malignancy and anticancer treatments, patients with advanced lung cancer may be at a higher risk of COVID-19 infection. During epidemic of COVID-19, a guideline for the optimal management of patients with advanced lung cancer urgently needs to be proposed to distinguish the symptoms of COVID-19 and the side effects of antitumor drugs. This network questionnaire survey was conducted on the lung cancer group of the Chinese Thoracic Society, Chinese Medical Association; the lung cancer group of the Chinese Society of Clinical Oncology Youth Committee; and the Chinese Respiratory Oncology Collaboration. 321 valid questionnaires were received. Based on the guidelines on lung cancer and the results of the questionnaires, a consensus was reached. During the epidemic of COVID-19, We recommended that patients with advanced NSCLC should be treated as outpatients as possible at the nearest medical center; Patients who need to be hospitalized for antitumor treatment should be excluded from COVID-19 infection; More intensive attention should be paid to identification of COVID-19-related symptoms and adverse reactions caused by the malignancy or antitumor treatments. Stronger personal protection should be made for advanced NSCLC patients; An intentional postponing of antitumor treatment should be considered according to patient performance status. Treatment strategies should be made according to different types of advanced NSCLC patients and efficacy and toxicity of drugs.","Zhonghua Jie He He Hu Xi Za Zhi","32125132"],"abstract":["The outbreak of coronavirus disease 2019 (COVID-19) has become a public health emergency of major international concern. Given the systemic immunosuppressive state caused by malignancy and anticancer treatments, patients with advanced lung cancer may be at a higher risk of COVID-19 infection. During epidemic of COVID-19, a guideline for the optimal management of patients with advanced lung cancer urgently needs to be proposed to distinguish the symptoms of COVID-19 and the side effects of antitumor drugs. This network questionnaire survey was conducted on the lung cancer group of the Chinese Thoracic Society, Chinese Medical Association; the lung cancer group of the Chinese Society of Clinical Oncology Youth Committee; and the Chinese Respiratory Oncology Collaboration. 321 valid questionnaires were received. Based on the guidelines on lung cancer and the results of the questionnaires, a consensus was reached. During the epidemic of COVID-19, We recommended that patients with advanced NSCLC should be treated as outpatients as possible at the nearest medical center; Patients who need to be hospitalized for antitumor treatment should be excluded from COVID-19 infection; More intensive attention should be paid to identification of COVID-19-related symptoms and adverse reactions caused by the malignancy or antitumor treatments. Stronger personal protection should be made for advanced NSCLC patients; An intentional postponing of antitumor treatment should be considered according to patient performance status. Treatment strategies should be made according to different types of advanced NSCLC patients and efficacy and toxicity of drugs."],"journal":"Zhonghua Jie He He Hu Xi Za Zhi","date":"2020-03-04T11:00:00Z","year":2020,"_id":"32125132","week":"202010|Mar 02 - Mar 08","doi":"10.3760/cma.j.cn112147-20200221-00138","keywords":["Advanced non-small cell lung cancer","COVID-19","Management"],"source":"PubMed","locations":["optimal"],"topics":["Treatment","Diagnosis","Prevention"],"weight":1,"_version_":1662334544051699712,"score":205.39127},{"pmid":32224232,"title":"COVID-19: Pandemic Contingency Planning for the Allergy and Immunology Clinic.","text":["COVID-19: Pandemic Contingency Planning for the Allergy and Immunology Clinic.","In the event of a global infectious pandemic, drastic measures may be needed that limit or require adjustment of ambulatory allergy services. However, no rationale for how to prioritize service shut down and patient care exists. A consensus-based ad-hoc expert panel of allergy/immunology specialists from the United States and Canada developed a service and patient prioritization schematic to temporarily triage allergy/immunology services. Recommendations and feedback were developed iteratively, using an adapted modified Delphi methodology to achieve consensus. During the ongoing pandemic while social distancing is being encouraged, most allergy/immunology care could be postponed/delayed or handled through virtual care. With the exception of many patients with primary immunodeficiency, patients on venom immunotherapy, and patients with asthma of a certain severity, there is limited need for face-to-face visits under such conditions. These suggestions are intended to help provide a logical approach to quickly adjust service to mitigate risk to both medical staff and patients. Importantly, individual community circumstances may be unique and require contextual consideration. The decision to enact any of these measures rests with the judgment of each clinician and individual health care system. Pandemics are unanticipated, and enforced social distancing/quarantining is highly unusual. This expert panel consensus document offers a prioritization rational to help guide decision making when such situations arise and an allergist/immunologist is forced to reduce services or makes the decision on his or her own to do so.","J Allergy Clin Immunol Pract","Shaker, Marcus S","Oppenheimer, John","Grayson, Mitchell","Stukus, David","Hartog, Nicholas","Hsieh, Elena W Y","Rider, Nicholas","Dutmer, Cullen M","Vander Leek, Timothy K","Kim, Harold","Chan, Edmond S","Mack, Doug","Ellis, Anne K","Lang, David","Lieberman, Jay","Fleischer, David","Golden, David B K","Wallace, Dana","Portnoy, Jay","Mosnaim, Giselle","Greenhawt, Matthew","32224232"],"abstract":["In the event of a global infectious pandemic, drastic measures may be needed that limit or require adjustment of ambulatory allergy services. However, no rationale for how to prioritize service shut down and patient care exists. A consensus-based ad-hoc expert panel of allergy/immunology specialists from the United States and Canada developed a service and patient prioritization schematic to temporarily triage allergy/immunology services. Recommendations and feedback were developed iteratively, using an adapted modified Delphi methodology to achieve consensus. During the ongoing pandemic while social distancing is being encouraged, most allergy/immunology care could be postponed/delayed or handled through virtual care. With the exception of many patients with primary immunodeficiency, patients on venom immunotherapy, and patients with asthma of a certain severity, there is limited need for face-to-face visits under such conditions. These suggestions are intended to help provide a logical approach to quickly adjust service to mitigate risk to both medical staff and patients. Importantly, individual community circumstances may be unique and require contextual consideration. The decision to enact any of these measures rests with the judgment of each clinician and individual health care system. Pandemics are unanticipated, and enforced social distancing/quarantining is highly unusual. This expert panel consensus document offers a prioritization rational to help guide decision making when such situations arise and an allergist/immunologist is forced to reduce services or makes the decision on his or her own to do so."],"journal":"J Allergy Clin Immunol Pract","authors":["Shaker, Marcus S","Oppenheimer, John","Grayson, Mitchell","Stukus, David","Hartog, Nicholas","Hsieh, Elena W Y","Rider, Nicholas","Dutmer, Cullen M","Vander Leek, Timothy K","Kim, Harold","Chan, Edmond S","Mack, Doug","Ellis, Anne K","Lang, David","Lieberman, Jay","Fleischer, David","Golden, David B K","Wallace, Dana","Portnoy, Jay","Mosnaim, Giselle","Greenhawt, Matthew"],"date":"2020-04-01T11:00:00Z","year":2020,"_id":"32224232","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.jaip.2020.03.012","keywords":["Allergic rhinitis","Allergy","Allergy immunotherapy","Angioedema","Asthma","Atopic dermatitis","COVID-19","Food allergy","Primary immunodeficiency","SARS-CoV-2","Urticaria","Venom allergy"],"source":"PubMed","locations":["Canada","United States"],"countries":["Canada","United States"],"countries_codes":["CAN|Canada","USA|United States"],"topics":["Prevention"],"weight":1,"_version_":1662819280347987968,"score":203.72295},{"pmid":32222433,"title":"[Guidelines for surgical management of gynaecological cancer during pandemic COVID-19 period - FRANCOGYN group for the CNGOF.]","text":["[Guidelines for surgical management of gynaecological cancer during pandemic COVID-19 period - FRANCOGYN group for the CNGOF.]","INTRODUCTION: recommendations for the management of patients with gynecological cancer during the COVID-19 pandemic period. MATERIAL AND METHOD: recommendations based on the consensus conference model. RESULTS: In the case of a COVID-19 positive patient, surgical management should be postponed for at least 15 days. For cervical cancer, the place of surgery must be re-evaluated in relation to radiotherapy and Radio-Chemotherapy-Concomitant and the value of lymph node staging surgeries must be reviewed on a case-by-case basis. For advanced ovarian cancers, neo-adjuvant chemotherapy should be favored even if primary cytoreduction surgery could be envisaged. It is lawful not to offer hyperthermic intraperitoneal chemotherapy during a COVID-19 pandemic. In the case of patients who must undergo interval surgery, it is possible to continue the chemotherapy and to offer surgery after 6 cycles of chemotherapy. For early stage endometrial cancer, in case of low and intermediate preoperative ESMO risk, hysterectomy with bilateral annexectomy associated with a sentinel lymph node procedure should be favored. It is possible to consider postponing surgery for 1 to 2 months in low-risk endometrial cancers (FIGO Ia stage on MRI and grade 1-2 endometrioid cancer on endometrial biopsy). For high ESMO risk, it ispossible to favor the MSKCC algorithm (combining PET-CT and sentinel lymph node biopsy) in order to omit pelvic and lumbar-aortic lymphadenectomies. CONCLUSION: During COVID-19 pandemic, patients suffering from cancer should not lose life chance, while limiting the risks associated with the virus.","Gynecol Obstet Fertil Senol","Vincent, Lavoue","Cherif, Akladios","Henri, Azais","Marcos, Ballester","Sofiane, Bendifallah","Pierre-Adrien, Bolze","Nicolas, Bourdel","Alexandre, Bricou","Geoffroy, Canlorbe","Xavier, Carcopino","Pauline, Chauvet","Pierre, Collinet","Charles, Coutant","Yohann, Dabi","Ludivine, Dion","Tristan, Gauthier","Olivier, Graesslin","Cyrille, Huchon","Martin, Koskas","Frederic, Kridelka","Lise, Lecointre","Matthieu, Mezzadri","Camille, Mimoun","Lobna, Ouldamer","Emilie, Raimond","Cyril, Touboul","32222433"],"abstract":["INTRODUCTION: recommendations for the management of patients with gynecological cancer during the COVID-19 pandemic period. MATERIAL AND METHOD: recommendations based on the consensus conference model. RESULTS: In the case of a COVID-19 positive patient, surgical management should be postponed for at least 15 days. For cervical cancer, the place of surgery must be re-evaluated in relation to radiotherapy and Radio-Chemotherapy-Concomitant and the value of lymph node staging surgeries must be reviewed on a case-by-case basis. For advanced ovarian cancers, neo-adjuvant chemotherapy should be favored even if primary cytoreduction surgery could be envisaged. It is lawful not to offer hyperthermic intraperitoneal chemotherapy during a COVID-19 pandemic. In the case of patients who must undergo interval surgery, it is possible to continue the chemotherapy and to offer surgery after 6 cycles of chemotherapy. For early stage endometrial cancer, in case of low and intermediate preoperative ESMO risk, hysterectomy with bilateral annexectomy associated with a sentinel lymph node procedure should be favored. It is possible to consider postponing surgery for 1 to 2 months in low-risk endometrial cancers (FIGO Ia stage on MRI and grade 1-2 endometrioid cancer on endometrial biopsy). For high ESMO risk, it ispossible to favor the MSKCC algorithm (combining PET-CT and sentinel lymph node biopsy) in order to omit pelvic and lumbar-aortic lymphadenectomies. CONCLUSION: During COVID-19 pandemic, patients suffering from cancer should not lose life chance, while limiting the risks associated with the virus."],"journal":"Gynecol Obstet Fertil Senol","authors":["Vincent, Lavoue","Cherif, Akladios","Henri, Azais","Marcos, Ballester","Sofiane, Bendifallah","Pierre-Adrien, Bolze","Nicolas, Bourdel","Alexandre, Bricou","Geoffroy, Canlorbe","Xavier, Carcopino","Pauline, Chauvet","Pierre, Collinet","Charles, Coutant","Yohann, Dabi","Ludivine, Dion","Tristan, Gauthier","Olivier, Graesslin","Cyrille, Huchon","Martin, Koskas","Frederic, Kridelka","Lise, Lecointre","Matthieu, Mezzadri","Camille, Mimoun","Lobna, Ouldamer","Emilie, Raimond","Cyril, Touboul"],"date":"2020-03-31T11:00:00Z","year":2020,"_id":"32222433","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.gofs.2020.03.017","keywords":["COVID-19","COVID-19- Recommandation","Cancer gynecologique","Guideline","Gynaecological cancer","Management","Prise en charge"],"source":"PubMed","locations":["ovarian"],"topics":["Treatment"],"weight":1,"_version_":1662715354818805761,"score":197.79716},{"pmid":32105052,"title":"[Surgical treatment for esophageal cancer during the outbreak of COVID-19].","text":["[Surgical treatment for esophageal cancer during the outbreak of COVID-19].","Since December 2019, unexplained pneumonia has appeared in Wuhan City, Hubei Province, and a new type of coronavirus infection was confirmed as COVID-19. COVID-19 spread rapidly nationwide and abroad. The COVID-19 has brought huge impacts to all the people and walks of life, especially to the medical and health systems. It has also brought great challenges to the treatment of patients with cancer. Esophageal cancer is a common malignant tumor in China and most of the patients are in the middle and advanced stage when diagnosed, with immunosuppressive and poor prognosis. The selection of surgical procedures and perioperative managements of esophageal cancer require all thoracic surgeons work together to figure out a reasonable system of surgical treatment and emergency response.","Zhonghua Zhong Liu Za Zhi","Li, Y","Qin, J J","Wang, Z","Yu, Y","Wen, Y Y","Chen, X K","Liu, W X","Li, Y","32105052"],"abstract":["Since December 2019, unexplained pneumonia has appeared in Wuhan City, Hubei Province, and a new type of coronavirus infection was confirmed as COVID-19. COVID-19 spread rapidly nationwide and abroad. The COVID-19 has brought huge impacts to all the people and walks of life, especially to the medical and health systems. It has also brought great challenges to the treatment of patients with cancer. Esophageal cancer is a common malignant tumor in China and most of the patients are in the middle and advanced stage when diagnosed, with immunosuppressive and poor prognosis. The selection of surgical procedures and perioperative managements of esophageal cancer require all thoracic surgeons work together to figure out a reasonable system of surgical treatment and emergency response."],"journal":"Zhonghua Zhong Liu Za Zhi","authors":["Li, Y","Qin, J J","Wang, Z","Yu, Y","Wen, Y Y","Chen, X K","Liu, W X","Li, Y"],"date":"2020-02-28T11:00:00Z","year":2020,"_id":"32105052","week":"20209|Feb 24 - Mar 01","doi":"10.3760/cma.j.cn112152-20200226-00128","keywords":["COVID-19","Diagnosis and treatment strategy","Esophageal neoplasms","Surgery"],"source":"PubMed","locations":["China","Hubei","Wuhan","thoracic"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Diagnosis"],"weight":1,"_version_":1662334544242540544,"score":196.0199},{"pmid":32218915,"pmcid":"PMC7097833","title":"National Institute for the Infectious Diseases \"L. Spallanzani\", IRCCS. Recommendations for COVID-19 clinical management.","text":["National Institute for the Infectious Diseases \"L. Spallanzani\", IRCCS. Recommendations for COVID-19 clinical management.","On January 9 2020, the World Health Organization (WHO) declared the identification, by Chinese Health authorities, of a novel coronavirus, further classified as SARS-CoV-2 responsible of a disease (COVID-19) ranging from asymptomatic cases to severe respiratory involvement. On March 9 2020, WHO declared COVID-19 a global pandemic. Italy is the second most affected country by COVID-19 infection after China. The \"L. Spallanzani\" National Institute for the Infectious Diseases, IRCCS, Rome, Italy, has been the first Italian hospital to admit and manage patients affected by COVID-19. Hereby, we show our recommendations for the management of COVID-19 patients, based on very limited clinical evidences; they should be considered as expert opinions, which may be modified according to newly produced literature data.","Infect Dis Rep","Nicastri, Emanuele","Petrosillo, Nicola","Bartoli, Tommaso Ascoli","Lepore, Luciana","Mondi, Annalisa","Palmieri, Fabrizio","D'Offizi, Gianpiero","Marchioni, Luisa","Murachelli, Silvia","Ippolito, Giuseppe","Antinori, Andrea","32218915"],"abstract":["On January 9 2020, the World Health Organization (WHO) declared the identification, by Chinese Health authorities, of a novel coronavirus, further classified as SARS-CoV-2 responsible of a disease (COVID-19) ranging from asymptomatic cases to severe respiratory involvement. On March 9 2020, WHO declared COVID-19 a global pandemic. Italy is the second most affected country by COVID-19 infection after China. The \"L. Spallanzani\" National Institute for the Infectious Diseases, IRCCS, Rome, Italy, has been the first Italian hospital to admit and manage patients affected by COVID-19. Hereby, we show our recommendations for the management of COVID-19 patients, based on very limited clinical evidences; they should be considered as expert opinions, which may be modified according to newly produced literature data."],"journal":"Infect Dis Rep","authors":["Nicastri, Emanuele","Petrosillo, Nicola","Bartoli, Tommaso Ascoli","Lepore, Luciana","Mondi, Annalisa","Palmieri, Fabrizio","D'Offizi, Gianpiero","Marchioni, Luisa","Murachelli, Silvia","Ippolito, Giuseppe","Antinori, Andrea"],"date":"2020-03-29T11:00:00Z","year":2020,"_id":"32218915","week":"202013|Mar 23 - Mar 29","doi":"10.4081/idr.2020.8543","keywords":["COVID-19","SARS-CoV-2","Treatment"],"source":"PubMed","locations":["China","Italian","Italy"],"countries":["China","Italy"],"countries_codes":["CHN|China","ITA|Italy"],"topics":["Treatment"],"weight":1,"_version_":1662540582040371200,"score":194.75258}]}